01:49 PM EST - Tryp Therapeutics Inc : Announced today that it has received confirmation from the U.S. Food and Drug Administration that its review of Tryp's Investigational New Drug application is complete and that the Company may proceed with its clinical study in fibromyalgia. Tryp is a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs. Tryp Therapeutics Inc
shares C.TRYP are trading up 0.01 cent at $0.23.
